Wall Street analysts predict that CTI BioPharma Corp (NASDAQ:CTIC) will report sales of $600,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for CTI BioPharma’s earnings, with the lowest sales estimate coming in at $500,000.00 and the highest estimate coming in at $700,000.00. CTI BioPharma posted sales of $1.71 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 64.9%. The business is expected to announce its next quarterly earnings report on Monday, November 5th.

On average, analysts expect that CTI BioPharma will report full year sales of $12.35 million for the current fiscal year, with estimates ranging from $12.10 million to $12.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $12.85 million per share, with estimates ranging from $10.70 million to $15.00 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow CTI BioPharma.

CTI BioPharma (NASDAQ:CTIC) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.23) by $0.03. The business had revenue of $0.61 million during the quarter, compared to the consensus estimate of $0.30 million. CTI BioPharma had a negative net margin of 313.77% and a negative return on equity of 90.92%.

Several analysts have issued reports on the stock. ValuEngine raised shares of CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Friday, August 3rd. Zacks Investment Research raised shares of CTI BioPharma from a “sell” rating to a “hold” rating in a research note on Tuesday, July 24th. Jefferies Financial Group reissued a “buy” rating and issued a $4.00 price objective on shares of CTI BioPharma in a research note on Friday, July 20th. BidaskClub downgraded shares of CTI BioPharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 14th. Finally, JMP Securities set a $8.00 price target on shares of CTI BioPharma and gave the company a “buy” rating in a research note on Tuesday, July 10th. Two analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. CTI BioPharma has an average rating of “Buy” and a consensus target price of $5.83.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of CTI BioPharma by 546.2% during the second quarter. BlackRock Inc. now owns 2,803,182 shares of the biopharmaceutical company’s stock valued at $13,958,000 after acquiring an additional 2,369,398 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of CTI BioPharma during the second quarter valued at approximately $547,000. Bank of New York Mellon Corp raised its stake in shares of CTI BioPharma by 203.7% during the second quarter. Bank of New York Mellon Corp now owns 150,671 shares of the biopharmaceutical company’s stock valued at $750,000 after acquiring an additional 101,055 shares in the last quarter. Rhumbline Advisers bought a new stake in shares of CTI BioPharma during the second quarter valued at approximately $243,000. Finally, Alps Advisors Inc. bought a new stake in shares of CTI BioPharma during the second quarter valued at approximately $419,000. 62.76% of the stock is owned by hedge funds and other institutional investors.

CTI BioPharma traded down $0.13, hitting $1.95, during trading on Monday, according to Marketbeat Ratings. The stock had a trading volume of 958,020 shares, compared to its average volume of 1,055,096. The company has a debt-to-equity ratio of 0.18, a current ratio of 4.28 and a quick ratio of 5.30. The company has a market cap of $124.10 million, a P/E ratio of -1.57 and a beta of -0.32. CTI BioPharma has a one year low of $1.94 and a one year high of $5.36.

About CTI BioPharma

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis.

Featured Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on CTI BioPharma (CTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CTI BioPharma (NASDAQ:CTIC)

Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.